DAIICHI SANKYO CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,330 JPY | +2.54% |
|
-3.13% | +37.65% |
| 07/05 | Japan's Nikkei closes at 3-week high on US rate-cut outlook, tech boost | RE |
| 07/05 | Japan's Nikkei climbs on Fed rate-cut outlook, tech boost | RE |
Presenter SpeechJunichi Onuma (Executives)Now we'd like to start Daiichi Sankyo's Conference C...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Calendar
31/07/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
5,198
JPY
Average target price
5,807
JPY
Spread / Average Target
+11.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.65% | 65.17B | |
| +32.36% | 698B | |
| +26.51% | 568B | |
| -4.40% | 358B | |
| +19.46% | 328B | |
| +3.50% | 283B | |
| +16.34% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +8.62% | 165B |
- Stock Market
- Equities
- 4568 Stock
- News Daiichi Sankyo Co., Ltd.
- Transcript : Daiichi Sankyo Company, Limited, Q2 2021 Earnings Call, Oct 30, 2020